Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge

Although immune checkpoint inhibitors (ICIs) have dramatically revolutionized the field of oncology over the last decade, severe immune-related adverse events (irAEs) are potentially life-threatening. In comparison with toxicities involving the skin, gastrointestinal tract and endocrine system, neph...

Full description

Bibliographic Details
Main Authors:	Martina Catalano, Giandomenico Roviello, Ilaria Camilla Galli, Raffaella Santi, Gabriella Nesi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Medicine
Subjects:	immune checkpoint inhibitors immune-related adverse events nephrotoxicity ICI-induced acute kidney injury multidisciplinary management
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1014257/full

Similar Items

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
by: Patricia Iranzo, et al.
Published: (2022-05-01)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
by: Harm Westdorp, et al.
Published: (2021-10-01)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01)

Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series
by: Antonella Laria, et al.
Published: (2021-08-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
by: Cristiane J. Gomes-Lima, et al.
Published: (2023-09-01)

Immune checkpoint inhibitors and acute kidney injury
by: Ping Zhou, et al.
Published: (2024-02-01)

Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors
by: Maria-Carlota Londoño, et al.
Published: (2020-11-01)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
by: Xueyan Wang, et al.
Published: (2022-10-01)

Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management
by: Krishna Moturi, et al.
Published: (2023-12-01)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
by: Giandomenico Roviello, et al.
Published: (2021-08-01)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
by: Betul Ibis, et al.
Published: (2023-06-01)

Nephrotoxicity of checkpoint inhibitors; a current challenge
by: Samaneh Zandifar, et al.
Published: (2024-01-01)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
by: Jing Xiang, et al.
Published: (2023-12-01)

A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
by: Yue Hu, et al.
Published: (2023-04-01)

Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature
by: Xuewei Li, et al.
Published: (2022-09-01)

Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study
by: Lucia Parlati, et al.
Published: (2023-05-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do
by: Concetta Zito, et al.
Published: (2022-11-01)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
by: Adrian Chye, et al.
Published: (2022-07-01)

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
by: Parneet K. Cheema, et al.
Published: (2022-02-01)

Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports
by: Caie Wang, et al.
Published: (2023-10-01)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
by: Xin Zhao, et al.
Published: (2022-06-01)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
by: Huixia Li, et al.
Published: (2023-04-01)

Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
by: Simona Coniac, et al.
Published: (2023-05-01)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
by: Mona A. Marie, et al.
Published: (2022-12-01)

Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database
by: Hou-Ting Kuo, et al.
Published: (2024-01-01)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
by: Scott S. Tykodi, et al.
Published: (2023-04-01)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
by: Hans Urban, et al.
Published: (2022-01-01)

Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
by: Calogera Claudia Spagnolo, et al.
Published: (2022-12-01)

Rapidly progressing dyspnea and retiform purpura
by: Bianca Y. Kang, MD, et al.
Published: (2022-12-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
by: Keita Saito, et al.
Published: (2022-04-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review
by: Ranferi Ocaña-Guzmán, et al.
Published: (2023-08-01)

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
by: Quentin Scanvion, et al.
Published: (2020-01-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)